Adverse Events Associated with Nifurtimox Treatment for Chagas Disease in Children and Adults
Ariel Berenstein, Nicolás Falk, Guillermo Moscatelli, Samanta Moroni, Nicolás González, F. Garcia-Bournissen, Griselda Ballering, Héctor Freilij, Jaime Altcheh
Abstract
< 0.001). ADRs were mainly mild and moderate. Severe ADRs were infrequent (1.2% in children and 0.9% in adults). Nutritional, central nervous, and digestive systems were the most frequently affected, without differences between groups. Treatment was discontinued in 31/320 (9.7%) patients without differences between groups. However, ADR-related discontinuations occurred more frequently in adults than in children (OR = 5.5, 95% CI = 1.5 to 24). Our study supports the safety of NF for ChD treatment. Delaying NF treatment due to safety concerns does not seem to be supported by the evidence. (This study has been registered in ClinicalTrials.gov under identifier NCT04274101.).